Intrexon (XON) Earns Daily News Impact Rating of 0.12

Press coverage about Intrexon (NYSE:XON) has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intrexon earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.4663936378501 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

Shares of XON opened at $16.97 on Thursday. The company has a quick ratio of 1.93, a current ratio of 2.16 and a debt-to-equity ratio of 0.01. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -18.45 and a beta of 1.05. Intrexon has a one year low of $10.26 and a one year high of $25.88.

Intrexon (NYSE:XON) last announced its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.09). The company had revenue of $43.80 million during the quarter, compared to analysts’ expectations of $60.43 million. Intrexon had a negative return on equity of 14.96% and a negative net margin of 57.66%. Intrexon’s revenue for the quarter was down 18.4% on a year-over-year basis. During the same period last year, the firm earned ($0.26) earnings per share. equities research analysts expect that Intrexon will post -0.86 earnings per share for the current year.

A number of analysts have recently weighed in on the company. Northland Securities reissued a “buy” rating and issued a $17.00 price objective on shares of Intrexon in a research report on Friday, March 2nd. Bank of America lowered their price objective on Intrexon from $21.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, March 2nd. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $18.00 price objective (down previously from $22.00) on shares of Intrexon in a research report on Monday, March 5th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $34.67.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Insider Buying and Selling by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with's FREE daily email newsletter.

Leave a Reply